- PathAI is a leading provider of AI-powered pathology solutions, specializing in digital pathology platforms that enhance laboratory workflows and clinical operations.
- In the past year, PathAI has launched the AISight® Dx v2.19, received FDA Breakthrough Device Designation for PathAssist Derm, and expanded its collaborations with Labcorp and MedStar Health for nationwide deployment of its digital pathology solutions.
- Key partnerships include collaborations with Labcorp and MedStar Health, as well as a strategic alliance with University Hospital Zurich to enhance molecular pathology workflows.
- PathAI's ideal buyers are healthcare providers and pathology labs seeking to improve efficiency and accuracy in diagnostics, making it crucial for sales teams to engage with them as digital pathology adoption accelerates.
Engineering is PathAI’s largest group, employing 94 people and accounting for roughly one-third of total headcount, underscoring the importance of machine-learning research and product development. Marketing & Product (31 employees) and Business Management (28) follow, indicating a balanced emphasis on go-to-market execution and corporate strategy. Healthcare specialists number 28, while Information Technology supports the organisation with 27 staff members. Additional teams include Sales & Support (21), Finance & Administration (20), Human Resources (8), Consulting (8), and an "Other" category (15), illustrating a broad mix of scientific, technical, and business talent.
PathAI’s HQ in Boston, Massachusetts houses 104 employees, making it the company’s largest on-site presence. An additional 116 team members are classified under "Other" locations, highlighting a sizeable remote or distributed workforce. Outside of Boston, the most significant hubs are New York (19 employees) and San Francisco (12), complemented by smaller groups in Memphis, Los Angeles, San Diego, Minneapolis, Tucson, and Ann Arbor. This geographic spread allows PathAI to tap into diverse talent pools and remain close to pharmaceutical, biotechnology, and academic partners across the country.
